Elona Kogan - Nov 11, 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role: Director
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Stock symbol: APUS
Transactions as of: Nov 11, 2025
Transactions value $: $0
Form type: 4
Date filed: 11/13/2025, 06:28 PM
Previous filing: Oct 24, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kogan Elona	Director	C/O APIMEDS PHARMACEUTICALS US, INC., 100 MATAWAN ROAD, SUITE 325, MATAWAN	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	2025-11-13	0001679971

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APUS	Stock Option (right to buy)	Award	$0	+10K		$0.00	10K	Nov 11, 2025	Common Stock, par value $0.01 per share	10K	$2.67	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan.

Content

The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan.